Definitive Healthcare Appoints Clay Ritchey as CEO
Definitive Healthcare (DH) appointed Clay Ritchey as Chief Executive Officer and Board member, effective September 8, 2026, succeeding Kevin Coop, who departed on August 31, 2026 after serving as CEO since June 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Definitive Healthcare (DH) appointed Clay Ritchey as Chief Executive Officer and Board member, effective September 8, 2026, succeeding Kevin Coop, who departed on August 31, 2026 after serving as CEO since June 2024.
Ritchey brings over 25 years of experience in healthcare master data and technology. He most recently served as CEO of Verato and previously held senior roles at Evariant, Imprivata, Equinox Healthcare, Hill-Rom and Kronos. The company highlights his track record in driving profitable growth and his belief that AI will reshape healthcare, aligning with Definitive Healthcare’s upcoming AI-powered platform that combines proprietary healthcare data with conversational AI and workflows.
Positive
- New CEO with 25+ years of healthcare data and technology experience
- Leadership background as CEO of Verato and Evariant and CMO of Imprivata
- Board emphasizes Ritchey’s history of driving profitable growth in prior roles
- CEO alignment with company’s upcoming AI-powered platform launch
Negative
- CEO transition after roughly two years of prior CEO’s tenure may signal leadership instability
- Gap between former CEO’s departure on August 31, 2026 and new CEO’s effective date on September 8, 2026
Details
Market move: DH +15.26% in the Sep 2 session. CEO leadership change
On Sep 2, the day this news came out, DH closed 15.26% above the previous close. Argus tracked a peak move of +24.9% during that session. Our momentum scanner recorded 44 alerts for this stock that day. Relative volume reached 724.6x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 2 session.
Key Figures
- CEO appointment effective
- September 8, 2026
- Clay Ritchey appointed CEO and Board member
- Prior CEO departure
- August 31, 2026
- Kevin Coop departed as CEO and Board member
- Prior CEO tenure
- June 2024
- Kevin Coop began serving as CEO
- Healthcare experience
- More than 25 years
- Clay Ritchey's stated healthcare expertise
Historical Context
-
Revenue declined and the company reported a second-quarter net loss.
-
The company launched an early adopter program for its AI-powered platform.
-
The company announced the date and time of its second-quarter results call.
-
The company granted inducement RSUs to its incoming AI and data product leader.
-
Restaurant365 appointed a former Definitive Healthcare executive to a customer role.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
master data management technical
conversational ai technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Mr. Ritchey brings more than 25 years of deep healthcare expertise to Definitive
FRAMINGHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced that its Board of Directors has appointed Clay Ritchey as the Company’s next Chief Executive Officer and as a member of the Board of Directors, each effective September 8, 2026. Mr. Ritchey succeeds Kevin Coop, who departed as CEO and as a member of the Board of Directors, effective August 31, 2026. Mr. Coop had served as CEO since June 2024.
Jason Krantz, Chairman of the Board of Definitive Healthcare, said, “We are excited to welcome Clay as our new CEO. He is a visionary leader with more than 25 years of experience across the healthcare master data and technology markets. Clay has a proven track record of generating faster, durable, and profitable growth in his prior senior leadership roles. In addition, Clay has a deep conviction that AI is posed to fundamentally reshape healthcare and that Definitive Healthcare is uniquely positioned to lead that shift as the industry’s premier healthcare commercial intelligence player.”
Mr. Ritchey joins Definitive Healthcare after most recently serving as CEO of Verato, a leading healthcare master data management company. Prior to Verato, he held senior leadership positions at multiple healthcare focused companies, including as CEO of Evariant prior to its acquisition by Healthgrades, as CMO of Imprivata and CEO of Equinox Healthcare. Earlier in his career he held senior marketing and go-to-market positions with Hill-Rom and Kronos.
“I’m thrilled to be joining Definitive Healthcare to help accelerate the company’s return to growth,” said Mr. Ritchey. “Definitive Healthcare operates in a large and attractive market where our proprietary datasets and growing portfolio of solutions help customers solve critical business challenges that create extraordinary value. And with the upcoming release of our new AI powered platform, which combines our best-in-class healthcare data with conversational AI and workflows, our customers will be able to gain even more leverage and value from our powerful data assets. I’m excited to hit the ground running alongside our customers and employees to innovate faster and deliver consistent top and bottom-line growth.”
About Definitive Healthcare
Definitive Healthcare is a data and analytics company focused on the business side of healthcare. The healthcare market is complex — our data makes it clearer. We cut through the noise to deliver the insights that healthcare organizations and companies need to make smarter, faster, more strategic decisions. Because when our customers succeed, healthcare gets better for everyone. Learn more at definitivehc.com.
Forward-Looking Statements
This press release includes forward-looking statements that reflect our current views with respect to future events and financial performance. Such statements are provided under the “safe harbor” protection of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by words or phrases written in the future tense and/or preceded by words such as “likely,” “will,” “should,” “may,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “assumes,” “would,” “potentially” or similar words or variations thereof, or the negative thereof, references to future periods, or by the inclusion of forecasts or projections, but these terms are not the exclusive means of identifying such statements. Examples of forward-looking statements include, but are not limited to, statements we make regarding our outlook, financial guidance, the benefits of our healthcare commercial intelligence solutions, our overall future prospects, customer behaviors and use of our solutions, the market, industry and macroeconomic environment, our plans to improve our operational and financial performance and our business, our ability to execute on our plans, customer growth, including our upsell and cross-sell opportunities, and our ability to successfully transition executive leadership. Forward-looking statements in this press release are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include the following: global geopolitical tension and difficult macroeconomic conditions; actual or potential changes in international, national, regional and local economic, business and financial conditions, including tariffs, sanctions, trade barriers, recessions, fluctuating inflation, high interest rates, volatility in the capital markets and related market uncertainty; our inability to acquire new customers and generate additional revenue from existing customers; our inability to generate sales of subscriptions to our platform or any decline in demand for our platform and the data we offer; the competitiveness of the market in which we operate and our ability to compete effectively; the failure to maintain and improve our platform, or develop new modules or insights for healthcare commercial intelligence; the inability to obtain and maintain accurate, comprehensive or reliable data, which could result in reduced demand for our platform; the loss of our access to our data providers; the failure to respond to advances in healthcare commercial intelligence; an inability to attract new customers and expand subscriptions of current customers; our ability to successfully transition executive leadership; and the possibility that our security measures are breached or unauthorized access to data is otherwise obtained. Additional factors or events that could cause our actual performance to differ from these forward-looking statements may emerge from time to time, and it is not possible for us to predict all of them. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual financial condition, results of operations, future performance and business may vary in material respects from the performance projected in these forward-looking statements.
For additional discussion of factors that could impact our operational and financial results, refer to our Quarterly Report on Form 10-Q for the three months ended June 30, 2026 that will be filed following this earnings release, as well as our Current Reports on Form 8-K and other subsequent SEC filings, which are or will be available on the Investor Relations page of our website at ir.definitivehc.com and on the U.S. Securities and Exchange Commission (“SEC”) website at www.sec.gov.
All information in this press release speaks only as of the date on which it is made. We undertake no obligation to publicly update this information, whether as a result of new information, future developments or otherwise, except as may be required by law.
Website
Definitive Healthcare intends to use its website as a distribution channel of material company information. Financial and other important information regarding the Company is routinely posted on and accessible through the Company’s website at definitivehc.com. Accordingly, you should monitor the investor relations portion of our website at ir.definitivehc.com in addition to following our press releases, SEC filings, and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the “Email Alerts” section of our investor relations page at ir.definitivehc.com.
Investor Contact:
Brian Denyeau
ICR for Definitive Healthcare
brian.denyeau@icrinc.com
646-277-1251
Media Contact:
Bethany Swackhamer
bswackhamer@definitivehc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.